Background Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real-world data on the effectiveness of biological treatment. Objectives To analyse the long-term real-world outcome data of patients who are biologically na€ ıve with moderate-to-severe psoriasis after switching to biological treatment. Methods An observational study of patients who are biologically na€ ıve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) values were analysed at 3-5 months, 6-11 months and at least once after ≥ 1 year, up to 9 years after the switch to biological treatment. Results In total, 583 patients fulfilled the inclusion criteria. Of these, 399, 395 and 373 patients had observed outcome data beyond 1 year on the PASI, DLQI and EQ-5D, respectively, and 164, 168 and 152, respectively, were observed in at least three time periods after the switch. Significant (P < 0Á01) improvement in PASI, DLQI and EQ-5D scores was observed 3-5 months after the switch and sustained under the whole observation period. The mean PASI, DLQI and EQ-5D changed from 13Á5 AE 9Á1, 9Á0 AE 8Á1 and 0Á74 AE 0Á22, respectively, before the switch, to 4Á0 AE 3Á5, 3Á7 AE 4Á7 and 0Á79 AE 0Á21, respectively, 1-5 years after the switch. Conclusions Biological treatment, as used in clinical practice, shows a stable longterm effectiveness in all the measured dimensions, PASI, DLQI and EQ-5D.
What's already known about this topic?
• Biological treatment shows a good efficacy in clinical trials and a satisfactory effectiveness in observational studies.
• Most analyses have focused on short-term outcomes of single biological agents and less is known about the long-term outcomes in broader patient groups where personalized treatment may induce switching between biological agents.
What does this study add?
• Ten years of individual-level real-world data were used to analyse the long-term effectiveness of switching to biological treatment for people with moderate-tosevere psoriasis.
• Outcomes measured using the Psoriasis Area and Severity Index and two health-related quality-of-life instruments (Dermatology Life Quality Index and EuroQol-5D) show disease improvement 3-5 months after switching to biological treatment.
• The effect of biological treatment was stable thereafter for the entire observed time span.
Psoriasis is a chronic inflammatory skin disease with a prevalence of about 3%. 1, 2 Patients with mild disease are usually treated with topical treatments, whereas patients with moderate-to-severe disease require systemic treatments. Methotrexate is the most common form of systemic treatment, and since 2004 biological agents have been available for psoriasis treatment in Sweden.
Observational studies based on national registers constitute necessary complements to clinical trials as they represent the actual patient population in real life and make it possible to study the effects over a longer period. There are several psoriasis registers from which real-world data on the effectiveness of biological treatment have been reported, such as the British Association of Dermatologists Biologic Interventions Register (BADBIR), the Continuous Assessment of Psoriasis Treatment Use Registry with Biologics (BioCAPTURE) and the Psoriasis Longitudinal Assessment and Registry (PSOLAR). [3] [4] [5] [6] [7] PsoReg, the Swedish national register for systemic psoriasis treatment, 8, 9 was established in 2006 to follow up the long-term effectiveness and safety of biological agents. The inclusion criteria for PsoReg are patients using, or about to start using systemic psoriasis treatment. PsoReg registers the clinical outcome measure Psoriasis Area and Severity Index (PASI) and two patient-reported outcome measures for health-related quality of life (HRQoL), the Dermatology Life Quality Index (DLQI) and the EuroQol-5D (EQ-5D), at visits reflecting clinical practice intervals for this patient group. In a previous study based on data from PsoReg, outcomes of patients who were biologically na€ ıve who switched to biological treatment were analysed before switch and at first follow-up, where one-third of the patients had follow-up assessment less than 2 months after switching, one-third at between 2 and 3 months and one-third at more than 3 months after switching. 10 Patients significantly improved on both the PASI and the patient-reported quality-of-life measures. As most patients were observed relatively soon after switching, outcomes may have been underestimated if the full treatment effect had not yet been achieved. On the other hand, recent research suggests that drug antibodies may reduce the sustained clinical effectiveness of biological treatment [11] [12] [13] and the response among some patients might then be reduced over time. In that case, outcomes in the previous study may have overestimated the long-term effectiveness. The objective of this study was therefore to analyse the long-term changes in the PASI alongside dermatology-specific and generic HRQoL indices in patients with moderate-tosevere psoriasis who switched to a biological treatment. The study takes a patient perspective, thus focusing on what happens in clinical practice at assessments taking place during different follow-up time intervals. This research adhered to the Declaration of Helsinki guidelines and it was approved by the Ume a Ethical Review Board, Sweden. Patients were registered after informed consent was obtained. Both data and consent were collected electronically, to assure an effective logistic in this nationwide project.
Patients and methods
This analysis is based on 10 years of real-world data extracted from PsoReg in May 2016. The focus was on the consequences of switching to biological treatment overall, and not the effects of specific agents. The patient group consisted of individuals who were biologically na€ ıve with one assessment of outcomes before starting biological treatment (baseline) and at least one registration of outcomes after switching. To reflect real-world practice and long-term effects of biological treatment, patients could switch between different biological agents and were not constrained to having biological treatment during the whole study period. The study design meant that patients could have their initial switch to biological treatment at any point from 2007 to April 2015 and still have at least 1 year of follow-up after switching. Patients who were prescribed efalizumab as their first biological agent were excluded from the analysis as the drug was withdrawn in 2009.
The clinical outcome measure, the PASI, includes the severity of the three main signs of psoriasis (the average redness, thickness and scaliness of the lesions) weighted by the coverage of the body part affected (head, trunk, arms and legs). The score is on a scale of zero to theoretically 72, where a higher score indicates higher severity. 14 The DLQI is a dermatology-specific measure of patients' HRQoL. 15 The index relates to how the skin disease has affected the life of the patient over the past 7 days. The questionnaire consists of 10 questions in the following six dimensions: (i) symptoms and feelings, (ii) daily activities, (iii) leisure, (iv) work and school, (v) personal relationships and (vi) treatment, where each question has four alternative answers, 'not at all', 'a little', 'a lot' and 'very much', with scores of zero, one, two and three, respectively. The overall summary score aggregates the score of each item, ranging from zero (best health state) to 30 (worst health state).
The EQ-5D is a generic HRQoL measure, which is often used to estimate quality-adjusted life years (QALYs). QALYs have previously been used in dermatological studies and have shown good validity in patients with psoriasis. [16] [17] [18] QALYs are calculated by weighting the time period in which a patient is in a certain health state, with the HRQoL weight associated with that state. The EQ-5D questionnaire includes five dimensions, mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and, in EQ-5D-3L, each dimension has three levels of severity: (i) no problems, (ii) some or moderate problems, (iii) extreme problems, which results in 243 possible health profiles. 19 These health profiles are associated with utility weights. In this analysis the population-based utility weights from the U.K. 20 were used. The utility value generally is between zero and one, where one is equal to 'perfect health' and zero equal to 'death'. However, the value can be a negative number as one can think of health states being worse than death. 20 PsoReg does not contain HRQoL data measured by the EuroQol-visual analogue scales. The outcome assessments of the patients treated with biological treatment were analysed before the switch and at three prespecified follow-up intervals after the switch to biological treatment at 3-5 months, 6-11 months and at least one observation in the time interval 1 year and above (hereafter defined as ≥ 1 year). The choice of initial follow-period (3-5 months) was based on Swedish guidelines 21 recommending a follow-up assessment after initiation with biological treatment after 3-4 months. For patients with more than one assessment within an observation interval, the mean of these assessments was used in the analysis. The main analysis of the long-term development of clinical and HRQoL outcomes used two subsamples of patients. The first subsample included patients who had at least four assessments: before the switch, 3-5 months, 6-11 months and at least once ≥ 1 year after the switch. The interval ≥ 1 year was furthermore divided into 1-5 years and 6-9 years.
The second subsample included patients who had two assessments: before the switch and at least one assessment ≥ 1 year after the switch. Thus, the first subsample of patients is included in the second subsample, but relaxed the criteria of having at least four assessments. The presentation of results after switching for the second subsample was divided into 2-year intervals after switching; 1-2 years, 3-4 years, 5-6 years and 7-9 years, with pairwise comparison with the baseline assessment.
We conducted two sensitivity analyses to explore the robustness of the results on the group mean outcomes. The first sensitivity analysis excluded patients who had discontinued their biological treatment at some point during the study period. The second sensitivity analysis investigated the exclusion of patients with other forms of skin psoriasis than plaque psoriasis, such as pustular psoriasis.
Descriptive statistics of patient cohort characteristics before and at least 1 year after switching were obtained for comparison with other studies. The Wilcoxon signed-rank test was used to determine whether there was a difference in outcomes before and after switching to biological treatment. All statistical analyses were performed using Stata statistical software release version 14Á1 (StataCorp, College Station, TX, U.S.A).
Results
At the time of the data extraction there were 5435 patients registered in PsoReg. In total, 700 patients who were biological na€ ıve switched to biological treatment between January 2007 and May 2016. Patients without follow-up after initiation of biological treatment (n = 104) were excluded from the analysis as well as patients who were prescribed efalizumab as their first biological agent as the drug was withdrawn in 2009 (n = 13) (Fig. 1) .
In total, 583 patients fulfilled the basic inclusion criteria. Patient characteristics for the whole study population, as well as for the two subsamples, are presented in Table 1 . In the two subsamples, between 47% and 49% of the patients had etanercept prescribed as their first biological agent whereas 39-43% had adalimumab, 8-9% had ustekinumab and 2-3% had infliximab prescribed. Most patients in subsamples 1 and 2 had been prescribed one biological agent during the study period, with approximately 25% prescribed two and around 10% more than two different biological agents during the study period. Before switching to a biological treatment, between 76% and 80% of the patients had a PASI and/or DLQI ≥ 10 score, and between 25% and 31% had both PASI and DLQI ≥ 10 scores. Plaque psoriasis was the most common diagnosis and was registered for 92-96% of patients in the two subsamples and few had other forms of skin psoriasis.
The PASI was assessed within all three follow-up intervals (3-5 months, 6-11 months and at least once ≥ 1 year after switching) in 164 people (first subsample). Patient HRQoL was assessed using the DLQI in 168 patients and the EQ-5D in 152 patients. Figure 2 illustrates the outcome values, presented as the median and the interquartile range, in the PASI, the DLQI and the EQ-5D before switching and at the respective follow-up intervals. Median and mean values and the mean change in outcomes since baseline are presented in Table 2 . Significant change (P < 0Á01) was found in all outcome variables (PASI, DLQI and EQ-5D) at each assessment compared with baseline. Significant differences were also found in PASI (n = 24) and DLQI (n = 25) for the subgroup of patients with at least one assessment 6-9 years after baseline. We also noted a higher mean level of PASI before switching in the latter group compared with patients with maximum 5-year follow-up (n = 140) (mean 15Á2 AE 8Á3 vs. 13Á2 AE 9Á2). As shown in Figure 2 , the changes in PASI, DLQI and EQ-5D scores are observed already at 3-5 months after switching to a biological treatment; thereafter the effect appears to stabilize. Figure 3a -c presents clinical and HRQoL outcomes for nearly 400 patients who had assessments before switching and at least once ≥ 1 year after switching to a biological treatment but where we relaxed the requirement of observations at four assessments. Results show a similar pattern with sustained long-term outcomes as in the more restricted first subsample.
Pairwise comparisons with baseline showed a sustained improved outcome (P < 0Á01), except for the EQ-5D at 5-6 years and 7-9 years.
The results from the sensitivity analyses excluding patients with a registered termination of biological treatment during the study period (between 12% and 15% of patients depending on the analysis) or excluding patients with other forms of skin psoriasis than plaque psoriasis (between 4% and 8% of patients depending on the analysis) demonstrated a similar pattern of results.
Outcomes for patients not included in the two main subsamples, namely patients with follow-up after 3 months but not beyond 1 year, showed the same tendency of improvements already at 3-5 months as in the main analyses for the subsamples (data in Table S1 ; see Supporting Information).
Discussion
We analysed long-term effects of biological treatment in moderate-to-severe psoriasis based on 10 years of real-world data from PsoReg, the national Swedish register for systemic psoriasis treatment. Significant differences between before and after the switch to biological treatment were found for all outcome variables (PASI, DLQI and EQ-5D) at 3-5 months after switching, and the changes were sustained over the entire observed time span. This pattern was stable across subgroups where frequency of measurement varied and when excluding patients who had discontinued biological treatment or restricting the sample to only plaque psoriasis. The strength of this study is that the analysed effects of initiating biological treatment on clinical and HRQoL outcomes are based on real-world data as opposed to efficacy analysed in randomized clinical trials with selected study populations in an experimental setting. Further, the study analysed the longterm effects of biological treatment overall, which has not been the subject of extensive previous research. Our results confirm the trend indicated in the previous PsoReg study where the mean follow-up was 112 AE 136 days between switching and assessment, with about one-third of patients having no more than 2 months of follow-up. 10 The results indicate that the full results of the treatment had not yet been seen because of too short a follow-up time in this previous study. Previous studies on the long-term effects of biological treatment in psoriasis have predominantly been extensions of clinical trials [22] [23] [24] [25] [26] focusing on single agents. Also, earlier real-world studies on the long-term effects of biological treatment [27] [28] [29] [30] and previous register-based studies 3-7 focused on single agents. In contrast, the motivation of the present study was to adopt a patient perspective focusing on the outcomes for patients rather than on specific agents, allowing patients to switch between treatments, which results in a less selected patient group. We found only one small longitudinal, retrospective study (n = 54) from Australia that also studied outcomes of biological treatment broadly. 31 Chaptini et al. investigated patients with biological treatment for at least 2 years up to 6Á5 years and found that PASI and DLQI scores decreased rapidly over the first 12 months and then remained low or even declined further. The same tendency of sustained effects was observed in our study. However, Chaptini et al. 31 reported a baseline mean PASI score > 25
and mean DLQI > 20, indicating that their patient group was worse off compared with the average level in our PsoReg sample. (18) 44 (27) 45 (27) 41 (27) 96 (24) 94 (24) 91 (24) > 2
35 (6) 21 (13) 20 (12) 18 (11) 35 (9) 34 (8) 31 (8) Number of years since switch, mean AE SD
PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQol-5D. a Subsample 1: patients with four assessments, before switching and 3-5 months, 6-11 months and 1-9 years after switching. b Subsample 2: patients with two assessments, before and 1-9 years after switching.
Fig 2.
Outcome values (median of means and interquartile range) in the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) before switching and at follow-up of patients with four assessments (subsample 1): 3-5 months, 6-11 months, 1-5 years (PASI n = 164, DLQI n = 168, EQ-5D n = 152) and 6-9 years after switching (PASI and EQ-5D n = 24, DLQI n = 25) to biological treatment.
Another observation in our study is that patients with the longest follow-up (6-9 years), and therefore people who switched when biological treatment in psoriasis was new, had the highest PASI: PASI mean 15Á2 AE 8Á3, followed by the intermediate group (1-5 years follow-up) 13Á2 AE 9Á2 and finally the < 12-month follow-up group 10Á5 AE 7Á4. This pattern is in line with the general observation that new treatments are first provided to patients whose condition is of the greatest severity and then the patient population is gradually extended to broader patient groups.
None of the studies in our review captured the EQ-5D. This study adds long-term data on the EQ-5D for patients with moderate-to-severe psoriasis in addition to long-term data on the PASI and DLQI. Most long-term studies are using only PASI scores as the outcome measure even though some studies also include the DLQI. The stable EQ-5D values presented here are in line with previously reported EQ-5D values from a Swedish population-based study 32 covering people in ages corresponding to the mean age of our PsoReg sample. Significant differences in EQ-5D before and after switching were found for all cohorts except for the cohort with the longest time interval from initiation (6-9 years) and this is probably explained by the small sample size (n = 24). The EQ-5D results are a useful measure for economic evaluations of biological agents in psoriasis as the EQ-5D has shown good validity in patients with psoriasis. [16] [17] [18] Correlations between the EQ-5D and the other measures have not been investigated in the current study but have been elsewhere. 33, 34 Limitations of the study include two sorts of selection bias: (i) although PsoReg to date has registered > 5500 patients with moderate-to-severe psoriasis in Sweden, recruitment has been gradual (between 2007 and 2015) with increasing numbers of patients switching to biological treatment and (ii) the study inclusion criteria required multiple registrations that by design limit the coverage of patients who see their doctor less frequently, for instance because of favourable outcomes or because of barriers to care including access. Both types of selection bias issues are inherent in real-world register data where diffusion of new treatments is gradual, registration nonmandatory and follow-up time not limited by a study protocol. The magnitude of these potential biases is by definition intangible but the low number of patients with the longest follow-up (6-9 years) is a result of clinical practice where few patients were prescribed biological treatment during the start-up phase, subject to restrictions and cautiousness.
Our analysis was limited to switching from a conventional systemic treatment to biological treatment and switches between different types of biological treatment were not investigated per se. However, data from clinical trials 35 and an earlier observational study based on data from PsoReg, indicate that patients with continuous biological treatment tend to achieve better outcomes than intermittently treated patients. 36 Thus, our analysis also includes those patients who for one reason or another needed to switch or terminate biological treatment, which might influence the observed treatment effect in this study. Further research is needed about realworld treatment patterns and switches in clinical practice as the effect of one drug may decrease over time and switches between agents may be needed to sustain good treatment outcomes.
37 Table 2 Median and mean values on the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) of patients with four assessments before switch and at follow-up 3-5 months, 6-11 months, 1-5 years and 6-9 years after switching to biological treatment Median P-value Mean AE SD Change, mean AE SD PASI (n = 164) Before switch 11Á6 1 3 Á5 AE 9Á1 3-5 months after switch 3Á0 < 0Á001 4Á5 AE 4Á3 9 Á0 AE 8Á8 6-11 months after switch 2Á6 < 0Á001 4Á1 AE 5Á0 9 Á4 AE 8Á1 1-5 years after switch 3Á1 < 0Á001 4Á0 AE 3Á5 9 Á5 AE 8Á4 6-9 years after switch a 2Á0
< 0Á001 5Á4 AE 7Á6 9 Á7 AE 8Á4 DLQI (n = 168) Before switch 7Á0 9 Á0 AE 8Á1 3-5 months after switch 1Á3 < 0Á001 3Á6 AE 5Á2 5 Á4 AE 7Á9 6-11 months after switch 1Á4 < 0Á001 3Á6 AE 5Á3 5 Á4 AE 8Á2 1-5 years after switch 2Á0 < 0Á001 3Á7 AE 4Á7 5 Á3 AE 7Á9 6-9 years after switch b 1Á0 0 Á003 2Á9 AE 4Á0 4 Á9 AE 8Á2 EQ-5D (n = 152) Before switch 0Á73 0Á74 AE 0Á22 3-5 months after switch 0Á80 < 0Á001 0Á82 AE 0Á19 0Á08 AE 0Á22 6-11 months after switch 0Á85 < 0Á001 0Á82 AE 0Á21 0Á09 AE 0Á22 1-5 years after switch 0Á83 0Á003 0Á79 AE 0Á21 0Á05 AE 0Á23 6-9 years after switch This careful analysis of 10 years of PsoReg data shows that the scarcity of outcome measures assessed at visits to healthcare providers over time limits the potential power of realworld data. In the future, e-health solutions may provide a means for patients to register continually their outcomes independently to complement data derived from visits to healthcare providers and thus grasp the full potential of a register.
In conclusion, our results suggest that the clinical and HRQoL effectiveness of biological treatment as used in clinical practice is sustained over time. The results from this study may support clinicians in initiating and continuing biological treatment for patients with disappointing outcomes using conventional treatment.
